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The present work comprises the synthesis of enoxacin (Heno) complexes with various transition metals. Two types of complexes
[M(eno)2(H2O)2]3H2O(M = Cu
II,N i
II or Mn
II) and [M(eno)(H2O)2]Cl · 4H2O( M= Fe
III) were obtained. The complexes were
characterized by diﬀerent physicochemical, spectroscopic, and elemental analysis. Results suggest that enoxacin interacts with
the metals as a monoanionic bidentate ligand. These complexes were also tested for their antibacterial activity against eleven
(11) diﬀerent microorganisms, and the results were compared with the parent drug. Moreover all the metal complexes were also
tested for their ability to scavenge reactive oxygen species where by Mn
II and Cu
II complexes exhibited potential to mediate anti-
inﬂammatory response.
Copyright © 2009 Saeed Arayne et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Enoxacin,1-ethyl-6-ﬂuoro-1,4-dihydro-4-oxo-7-(1-pipera-
zinyl)-1,8-naphthyridine-3-carboxylic acid is a potent inhi-
bitor of the bacterial enzyme DNA gyrase, exhibiting
high antibacterial activity against a broad spectrum of
Gram-negative and moderate activity against Gram-positive
bacteria [1–3]( Figure 1).
The most important structural features necessary for
meaningful antibacterial activity of enoxacin include a
carboxylic acid attached to the 3-position of the quinolone
nucleus and an alkyl group in the 1-position. In addition
to this, ﬂuorine attached to the 6-position and a nitrogen
heterocycle attached to the 7-position is also required for
their activity. This heterocycle in enoxacin is a piperazine
derivative [4]. Isosteric replacements of nitrogen for carbon
atom at postion 8 (1,8-napthyridines) are consistent and
retained the antimicrobial activity [5].
Quinolones are complexing agents for a variety of
metal ions including alkaline earth and transition metal
ions. Although reports indicate that the coordination of
quinolones to metal ions such as CuII,M g II,a n dC a II appear
to be important for the activity of the quinolone antibiotics
[6], it has a detrimental eﬀect on their absorption [7]. Early
studies by Nakano demonstrated the ability of the quinolone
naldixic acid to complex a variety of metal ions [8]. The
crystal structures of quinolone complexes [9, 10] indicate
that quinolone antibiotics can participate in the formation
of complexes in a number of ways. Complexes isolated
from acidic media usually contain singly and/or doubly
protonated quinolones that are incapable of bonding to the
metal ion and in these cases only electrostatic interaction
was observed between the drug and the metal ions [11,
12]. In other cases [13, 14], it was found that neutral
quinolones in the zwitterionic state are capable of forming
simple complexes. In these complexes the quinolone acts as a
bidentate ligand through the ring carbonyl group at position
4 and through one of the oxygen atoms of the carboxylato
group at position 3. Quinolones can also act as bridging
ligands and thus capable of forming polynuclear complexes.
Literature review reveals that there are few studies on the
interaction of metal ions with enoxacin [15]. Accordingly, an
attempt is made to study the interaction of enoxacin with
transition metals of biological interest and to investigate the
coordination chemistry of such interactions.
In the present work, we describe the synthesis and
characterization of metal complexes of enoxacin. Moreover
the antibacterial and anti-inﬂammatory activity of enoxacin2 Bioinorganic Chemistry and Applications
Table 1: Physicochemical Parameters of Enoxacin and its metal complexes.
S.No Complexes Color Melting point ◦C Mole Ratio % yield
1E n o x a c i n o ﬀ white 225 —
2M n II complex oﬀ white 265d 1 : 2 78
3F e III complex dark brown 275d 1 : 1 70
4N i II complex leaf green 246 1 : 2 76
5C u II complex light blue 255 1 : 2 72
N N
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Figure 1: Enoxacin.
metal complexes is also evaluated and compared with the
parent. Results suggest that metal interaction in some cases
signiﬁcantly altered the activity of enoxacin.
2. Experimental
2.1. Physical Measurements. Prior to the synthesis of the
metal complexes, the metal:drug ratios were determined by
conductometric titration and continuous variation method
(jobs plot). Conductometry was carried on Vernier LabPro.
DataacquisitionandanalysiswascarriedoutbyusingLogger
pro 3.2 software. For jobs plot the UV-Vis spectra of the drug
and metal solutions (in diﬀerent combination ratios) were
recorded on UV-Vis spectrophotometer (Shimadzu 1601
coupled with a P IV–PC and loaded with UVPC version 3.9,
software). Thin layer chromatography (TLC) was performed
on HSF-254 TLC plate and the samples were visualized
under UV lamp. Melting point of the metal complexes was
recorded on a Gallenkamp apparatus. The characterization
of enoxacin metal complexes was carried out by Fourier
Transform Infrared Spectrophotometer (Shimadzu Prestige-
21 200 VCE), coupled to a P IV-PC and loaded with IR
Resolution software. The disks were placed in the holder
directly in the IR laser beam. Spectra were recorded at
ar e s o l u t i o no f2 c m −1, and 50 scans were accumulated.
NMR spectra were recorded on Bruker AMX 500MHz
spectrometer in CD3OD using TMS as an internal standard.
Column chromatography was performed on Merck silica gel
60 (particle size 0.06–0.02).
2.2. Synthesis of Metal Complexes. Enoxacin base was a kind
gift from Zafa Pharmaceutical Laboratories Ltd., Karachi,
Pakistan. The metal salts used were of analytical grade. All
the glassware was washed with chromic acid followed by a
thorough washing with deionized water which was freshly
prepared in the laboratory.
Synthesis of metal complexes of enoxacin was carried out
according to their calculated mole ratios. For this purpose
enoxacin along with ferric chloride hexahydrate, manganese
chloride monohydrate, nickel chloride hexahydrate, and
copper chloride di hydrate were puriﬁed by recrystallization.
Solvent used for the synthesis of these complexes was double
distilled methanol.
The FeIII complex was synthesized by dissolving 1mmole
(0.27gm) of the metal salt and 1mmole (0.32gm) of the
drug separately in equal volume of hot methanol (20mL)
and then mixing the two solutions with constant stirring
in a round bottomed ﬂask. The ﬂask was ﬁtted to water
condenser, and the solution was reﬂuxed for about an
hour. The completion of the reaction was monitored by
TLC. Solvent system used was water, ethyl acetate, and
acetic acid in the ratio 1 : 2 : 1. In a similar way
other metal complexes were synthesized taking 1mmole
( 0 . 1 4 4 g m )o fM n II salt, 1mmole (0.2374gm) of NiII salt,
1mmole (0.161gm) of CuII salt, and 2mmole (0.64gm)
of the drug. The volume of the reaction mixture was then
reduced by rotary evaporation. The precipitated complexes
were ﬁltrated oﬀ, washed with water and methanol and
vacuum dried. The physical characteristics of enoxacin metal
c o m p l e x e sa r eg i v e ni n( Table 1).
2.3. Antibacterial Studies. Disk Diﬀusion technique devel-
oped by Bauer et al. [16] was adopted to determine the
antibacterial activity of enoxacin and all the metal complexes
against 11 diﬀerent clinical isolates of Gram-positive and
Gram-negative organisms, that is, Klebsiella Pneumoniae,
Proteus mirabilis, Staphylococcus aureus, Cornybacterium
hoﬀmini, Shigella ﬂexneri, Escherichia coli, Pseudomonas
areuginosa, Bacillus species, Citrobacter species,Streptococcus
pneumonia, and Salmonella typhi.
The antibacterial activity of the compounds (ligand,
metal salt, and complexes) was determined at a concentra-
tion range of 10mg/disc, 15mg/disc, and 20mg/disc. All the
solutions were prepared in hot methanol. The discs were
applied on the surface of the agar plate over which a culture
of microorganism was already streaked. After 24 hours of
incubation the clear zone of inhibition around the disc was
determined; this was related to the activity of the compound
against the test strain. Three replicas were made for each
treatment to minimize error.
2.4. Phagocyte Chemiluminescence. Luminol-enhanced che-
miluminescence assay was performed using Helfand et al.
protocol [17]. Brieﬂy whole blood diluted in modiﬁedBioinorganic Chemistry and Applications 3
Table 2: CHN Microanalysis of Enoxacin and its metal Complexes.
S.No Compound name C H N Chloride Metal
1 Enoxacin Found 56.42 5.85 16.99 — —
Calculated 56.24 5.35 17.49
2 [Mn(eno)2(H2O)2]·3H2O Found 45.40 6.12 14.04 — 7.05
Calculated 45.90 5.92 14.34 — 6.99
3 [Fe(eno)(H2O)2]·Cl·4H2O Found 33.67 5.27 10.47 13.2 10.43
Calculated 33.73 5.20 10.58 13.5 10.24
4 [Ni(eno)2(H2O)2]·3H2O Found 45.53 5.74 14.01 — 7.77
Calculated 45.65 5.62 14.19 — 7.43
5 [Cu(eno)2(H2O)2]·3H2O Found 45.39 5.56 14.12 — 8.02
Calculated 45.37 5.58 14.11 — 8.00
Hank‘s solution (MHS) was incubated with diﬀerent con-
centrations of the metal complexes (50, 25, and 5 μg/mL)
for 30 minutes Zymosan (Sigma Chemical Co., USA) 100μL
(20mg/mL), followed by 100μL( 7×105 M) luminal (Sigma
Chemical Co., USA) added to make a ﬁnal volume of
0.25mL.
MHS alone was run as a control. Peak chemilumines-
cence of the drug and the complexes was recorded with
a luminometer (Labsystem Luminoskan RS, Finland). The
luminometer was set with repeated scan mode, 50 scans with
30s intervals and one second point measuring time. The
experiments were performed three times to minimize errors.
3. Result andDiscussion
Enoxacin has a favorable solubility in acidic or basic solvents
and in hot water. However the metal complexes of enoxacin
were insoluble in hot water. Solubility was found in hot
methanol, ethanol, and chloroform. The complexes were
f o u n dt ob es t a b l ea tr o o mt e m p e r a t u r ef o rt w od a y s[ 18].
The stability was checked by taking melting points of the
c o m p l e x e sa ta ni n t e r v a lo f2 4h o u r sa n d4 8h o u r s .A l l
the samples were stored in room temperature (25
◦C). No
appreciable changes in the melting points were observed,
and the estimated error was ±1◦C. Melting points of the
metal complexes when compared with the reference drug
(Table 1)diﬀerconsiderablyfromenoxacin.Conductometric
titration (Figure 2) and jobs plot reveal that the metal:
drug complexes are in the ratio 1 : 1 (metal = FeIII)a n d
1 : 2 (metal = CuII,N i II or MnII). Argentometric titration
of Iron(III) complex using Potassium dichromate as an
indicator shows one molecule of chloride ion present outside
the coordination sphere of the complex. The structure of the
complexes established form the elemental analyses agree well
with their proposed formulae (Table 2).
In the IR spectra of enoxacin, two strong absorption
peaks at 1690 and 1640cm−1 are observed due to carboxylic
and ring ketonic (C=O) groups, respectively.
On comparing the IR spectrum of enoxacin with its
metal complexes it is found that the band due to carboxylic
group at (1690cm−1) nearly diminishes in the spectra of the
complexes indicating the coordination of this moiety to the
metal ions [19]. Further the absorption of the ring ketone
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Figure 2: Representative conductance graph of Enoxacin and its
MnII complex.
appears at a lower frequency near (1600cm−1) in the spectra
of the complexes which also suggests the binding of enoxacin
to the metal ions through the ring carbonyl oxygen atom
[20]. A broad diﬀuse band of medium intensity in the region
(3100–3500cm−1) is assigned to the OH stretching vibration
of the water molecules [21].
Important 1H NMR signals of enoxacin are observed at
chemical shifts of 1.40 (t, 3H, J = 7.0Hz, –CH3 methyl),
2.0 (s, 1H, amine), 2.62 (s, 4H, piperazine), 3.85 (s, 4H,
piperazine), 4.48 (q, 2H, J = 7.0Hz, –CH2– ethyl), 8.10, 8.95
(s, 2H, naphthyridine), and 11.0 (s, 1H, COOH).
On comparing main peaks of enoxacin with its com-
plexes, it is observed that all the signals of the free ligand are
present in the 1HNMR spectra of the complexes. The signals
for the aliphatic and piperazine protons are practically
unchanged since they lie far from the binding site of the
ligand [22]. However, resonance of naphthyridine proton
from 8.10–8.95 appeared down ﬁeld near 8.4–9.5ppm in the
spectra of all the complexes. Other studies also report that
the aromatic protons exhibit a characteristic 0.3–0.5ppm
downﬁeld shift upon binding of the quinolones to the diva-
lent metal ion [23]. The resonance of the carboxylic proton
(COOH) is not detected in the spectra of the complexes
which further suggest the coordination of enoxacin through
its carboxylate oxygen atoms [24]. The OH proton peak4 Bioinorganic Chemistry and Applications
Table 3: Zone of inhibition (mm) of enoxacin and its metal complexes.
Sample
Clostridium hofmani Staphylococcus aureus Bacillus subtilis Shigella ﬂexneri
Conc. (mg/disc) Conc. (mg/disc) Conc. (mg/disc) Conc. (mg/disc)
5 10 20 5 10 20 5 10 20 5 10 20
Enoxacin 8 14 16 8 10 14 8 10 12 8 11 13
E n o x + M n 1 01 6 2 0 1 52 0 2 1 1 21 5 1 6 8 9 1 3
Enox + Fe 8 10 10 10 10 10 7 9 11 7 8 10
Enox + Ni 14 18 24 7 10 10 10 12 16 10 11 15
E n o x + C u 1 11 3 1 7 1 41 5 2 0 1 01 1 1 1 8 1 1 1 2
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Figure 3: Tentative structure of CuII,M n II,a n dN i II complexes of
enoxacin.
appears near 3.5ppm, adjacent to the piperazine protons,
due to the presence of lattice water.
Our studies suggest that enoxacin acts as a monoanionic
bidentate ligand and interacts with the metal centre through
the 3-carboxylate and 4-oxygen atom. From the results
obtained, it is proposed that the Manganese(II), Nickel(II),
and Copper(II) complexes are probably six coordinate with
two molecules of enoxacin chelating the central metal atom
from four sides and two molecules of water at the vertices
of an octahedron (Figure 3). Alternatively, the enoxacin
complex of Iron(III) is four coordinate with probably one
molecule of the drug and two molecules of water along
the edge of a tetrahedron (Figure 4). Despite the crystalline
nature of the products, we did not manage to obtain
crystals suitable for determination of structures with X-ray
crystallography [21, 22].
3.1. Antibacterial Studies. The zone of inhibition around
the antibiotic discs is related to the susceptibility of the
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Figure 4: Tentative structure of FeIII complex of enoxacin.
organisms toward enoxacin and its metal complexes (Tables
3, 4,a n d5). Standard deviation values amongst replicate
responses were <0.6 indicating precision of the disc diﬀusion
method.
It was observed that Nickel(II) complex exhibited
increased antimicrobial eﬀect than enoxacin against all
the test strains except Staphylococcus aureus. Manganese(II)
complex showed improved activity against Staphylococcus
aureus and Bacillus subtilis while Copper(II) complex proved
to be more active against Citrobacter and Staphylococcus
aureus. Nearly all metal complexes showed increased activity
as compared to enoxacin against Clostridium hofmani except
Iron(III)complex,whichwasfoundtopossessreducedactiv-
ity against all the test strains as compared to enoxacin itself.
Activity of Manganese(II) and Copper(II) complexes was
depressed against Escherichia coli, Pseudomonas aeruginosa
andSalmonellatyphiwhileagainstStreptococcuspneumoniae,
Klebsiella pneumoniae, Shigella ﬂexneri, and Proteus mirabilis
no appreciable change in activity was observed probably due
to the intracellular biological conversion of the complexes
[25].
The increased activity of metal chelates can be explained
on the basis of the overtone concept and chelation theory.
According to the overtone concept of cell permeability, the
lipid membrane that surrounds the cell favors the passage
of only lipid-soluble materials in which liposolubility is anBioinorganic Chemistry and Applications 5
Table 4: Zone of inhibition (mm) of enoxacin and its metal complexes.
Sample
Pseudomonas areuginosa Salmonella typhi Streptococcus pneumonia Citrobacter
Conc. (mg/disc) Conc. (mg/disc) Conc. (mg/disc) Conc. (mg/disc)
5 10 20 5 10 20 5 10 20 5 10 20
Enoxacin 12 16 18 12 17 21 9 12 14 10 12 14
Enox +Mn 9 12 15 10 15 18 9 12 14 10 10 11
E n o x + F e 8 81 09 1 0 1 2 8 1 0 1 2 1 0 1 2 1 2
E n o x + N i 1 31 8 2 0 1 11 7 2 2 1 01 2 2 2 1 41 5 1 8
Enox + Cu 10 11 12 8 12 14 11 13 13 14 16 18
Table 5: Zone of inhibition (mm) of enoxacin and its metal complexes.
Sample
Escherichia coli Klebsiella pneumonia Proteus mirabilis
Conc. (mg/disc) Conc. (mg/disc) Conc. (mg/disc)
5 10 20 5 10 20 5 10 20
Enoxacin 12 15 19 9 12 13 10 13 14
E n o x + M n 1 2 1 31 41 1 1 1 1 2 1 0 1 11 3
Enox + Fe 10 11 12 9 11 11 11 13 12
E n o x + N i 1 4 1 62 51 1 1 4 1 8 1 0 1 22 0
E n o x + C u 1 0 1 21 21 0 1 1 1 3 1 1 1 31 3
important factor that controls the antimicrobial activity. On
chelation the polarity of the metal ion will be reduced to a
greater extent due to overlap of ligand orbital and partial
sharing of the positive charge of the metal ion with donor
groups. Further it increases the delocalization of π-electrons
over the whole chelate ring and enhances the lipophilicity of
complexes [26]. It is likely that the increased liposolubility
of the ligand upon metal complexation may contribute to
its facile transport into the bacterial cell which blocks the
metal binding sites in enzymes of microorganisms. These
complexes also disturb the respiration process of the cell and
thus block the synthesis of proteins, which restricts further
growth of the organism [24].
The antimicrobial activity of the metal salts was also
investigated. It was found that the metal salts did not exhibit
antimicrobial activity at the concentration range used to
assay the activity of the complexes in our work [22, 27].
3.2. Eﬀe c to nP h a g o c y t e sO x i d a t i v eB u r s t .I no r d e rt ot e s t
the immunomodulatory eﬀect of the drug and its metal
complexes, we investigated their eﬀect on the oxidative
burst activity of whole blood phagocytes. Phagocytic cells
on activation induce release of reactive oxygen free radicals
(oxidative burst) which is then quantiﬁed by a luminol-
enhanced chemiluminescence assay. Results indicate that the
zymosan-inducedoxidativeburstinwholebloodphagocytes
was inhibited (up to 50%) by Manganese(II) complex at
a concentration of 15.3 ± 0.7(μg/mL) while Copper(II)
complex produced 50% inhibition at a concentration of
18.7 ± 2.1(μg/mL). Both enoxacin and its Iron(III) and
Nickel(II) complex produced 50% inhibition at a concen-
tration above 50(μg/mL). Hence it is inferred that only
Manganese(II) and Copper(II) complexes showed moderate
inhibitory activity with IC50 ranging between 15–19μg/ml
while the drug and other complexes have negligible eﬀect
on the oxidative burst response. The molecular mechanism
causing the immunomodulatory eﬀects of ﬂuoroquinolones
and their complexes are still under investigation [28].
4. Conclusion
Many drugs possess modiﬁed toxicological and pharmaco-
logical properties when in the form of metal complexes [29].
Present work deals with the synthesis of enoxacin metal
complexes and the evaluation of the synergistic or antag-
onistic behavior of these complexes in comparison to the
parent, through the diﬀerence in their biological activities.
The complexes showed a diverse antimicrobial activity as
compared to enoxacin which is attributed to the formation
of metal drug chelates. Although complexation with metals
is known to boost biological activities of the quinolones;
yet in the form of Iron(III) complex, activity of enoxacin
was immensely decreased which may produce a detrimental
eﬀect in its therapeutic eﬃcacy. Nevertheless, complexation
with Nickel(II) resulted in improved antimicrobial proﬁle
of the drug while Manganese(II) and Copper(II) metal
complexesmodulatedoxidativeburstresponseofphagocytes
and unlike enoxacin could have potential to be anti-
inﬂammatory, as they suppressed the production of reactive
oxygen species.
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